Ab­b­Vie braces for 'greater ero­sion' of Hu­mi­ra fran­chise in sec­ond half of this year

Ab­b­Vie ex­ecs tout­ed a wave of Rin­voq pro­grams at Cowen’s an­nu­al con­fer­ence on health­care Tues­day as they brace for a tougher Hu­mi­ra bat­tle in the sec­ond half of this year.

Since its first ap­proval in rheuma­toid arthri­tis in 2002, Hu­mi­ra be­came one of in­dus­try’s top sell­ers ever, adding a wide list of in­di­ca­tions from ul­cer­a­tive col­i­tis to anky­los­ing spondyli­tis. The first biosim­i­lar to Hu­mi­ra, Am­gen’s Am­je­vi­ta, launched at the end of Jan­u­ary, and Ab­b­Vie ex­ecs an­nounced on the last quar­ter­ly call that they ex­pect a 37% drop in Hu­mi­ra sales this year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN